Cell therapy demand means CMOs need to up their capabilities, PharmSource

By Dan Stanton contact

- Last updated on GMT

GettyImages/Meletios Verras
GettyImages/Meletios Verras
There is a lack of third-party capabilities in the autologous cell therapy space says the new editor of PharmSource ahead of this year’s Interphex Convention.

Industry will converge on The Javits Center in New York City next week to discover the latest technologies and movements within the biopharma manufacturing space.

According to Fiona Barry, the new editor of PharmSource – a GlobalData product – on of the most hotly anticipated topics at this year’s show will be cell therapies, driven by the approvals of Novartis’ Kymriah (tisagenlecleucel)​ and Kite/Gilead’s Yescarta​ last year.

This is creating demand for contract manufacturing organisations (CMOs) which will need to fill gaps in their capabilities, especially for autologous therapies, Barry told Biopharma-Reporter.

Manufacturing capabilities needed for autologous cell therapies are not yet common, and most CMOs are not yet competent,”​ she said. “Our research shows there only approximately 30 companies involved in contract manufacturing autologous cell and tissue therapies​.”

There has been some action by CMOs to increase their cell therapy offering over the past year. Swiss manufacturer Lonza acquired PharmaCell in June​, for example, but most manufacturing, for now, is being done in-house.

Therefore CMOs need to build competency in a range of services to support reproducible production methods for autologous cell therapie, said Barry, including “growing human cells, assays, automation, and even in filling the skills gap among staff.”

Furthermore, there is a growing opportunity for other service areas to help support this growing space.

“Supply chain logistics are more important than ever for these therapies, because they represent the patient’s own irreplaceable cells and are often a last resort treatment,”​ Barry added. “Quality testing is also crucial for this vulnerable population.”

Related news

Related products

show more

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

biopharma-reporter-image

Inline diafiltration enables continuous processing

Pall Life Sciences | 13-Feb-2018 | Application Note

The Cadence inline diafiltration (ILDF) device is designed for continuous processing, in-process buffer exchange or contaminant removal in various processes...

Discover Fast and Simple Water Intrusion Testing

Discover Fast and Simple Water Intrusion Testing

Pall Life Sciences | 13-Nov-2017 | Application Note

At Pall we have supported the water intrusion test for more than 20 years and we developed the Palltronic® AquaWIT IV system to deliver fast and simple...

Related suppliers